Compared with the SST2 agonists [177Lu]Lu-DOTA-TOC [4] and [177Lu]Lu-DOTA-TATE [3], in vitro and in vivo experiments showed that [177Lu]Lu-satoreotide tetraxetan had a 10-fold higher activity bound to human carcinoid cells transfected with SST2 [4], induced more DNA double-strand breaks (DSBs) [3], and was associated with a longer median survival [3,4] and a longer mean period of tumour stabilisation [3]. Here, SSTR2 is linked to neoplasm.